Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 127-134

  White, Leonard ^a,b   Friedman, Joseph I ^a,b   Bowie, Christopher R ^b   Evers, Martin ^b   Harvey, Philip D ^b   Parrella, Michael ^a,b   Mihaila, Emilian ^b   Davis, Kenneth L ^b  

^a Pilgrim Psychiatric Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Cognition; Geriatric; Schizophrenia

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

AGED; AGED HOSPITAL PATIENT; ARTICLE; CHRONIC PATIENT; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNCTIONAL DISEASE; GERONTOPSYCHIATRY; HOSPITAL PATIENT; HUMAN; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SELF CARE; SKILL; SYMPTOM;

AGED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; FEMALE; HOSPITALIZATION; HUMANS; MALE; PATIENT ADMISSION; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SELF CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750605155     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.06.038     Document Type: Article

References (42)

1. Barak Y., Shamir E., and Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J. Clin. Psychopharmacol. 22 2 (2002) 115-120
2. Barak Y., Shamir E., Zemishlani H., Mirecki I., Toren P., and Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog. Neuro-psychopharmacol. Biol. Psychiatry 26 6 (2002) 1199-1202
3. Bowie C.R., Harvey P.D., Moriarty P.J., Parrella M., White L., Mohs R.C., and Davis K.L. Cognitive assessment of geriatric schizophrenic patients with severe impairment. Arch. Clin. Neuropsychol. 17 7 (2002) 611-623
4. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 4 (2001) 518-526
5. Davidson M., Harvey P., Welsh K.A., Powchik P., Putnam K.M., and Mohs R.C. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am. J. Psychiatry 153 10 (1996) 1274-1279
6. Davidson M., Harvey P.D., Vervarcke J., Gagiano C.A., De Hooge J.D., Bray G., Dose M., Barak Y., and Haushofer M. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int. J. Geriatr. Psychiatry 15 6 (2000) 506-514
7. Davis K.L., Buchsbaum M.S., Shihabuddin L., Spiegel-Cohen J., Metzger M., Frecska E., Keefe R.S., and Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biol. Psychiatry 43 11 (1998) 783-793
8. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 6 (2003) 553-564
9. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 3 (1975) 189-198
10. Friedman J.I., Harvey P.D., Coleman T., Moriarty P.J., Bowie C., Parrella M., White L., Adler D., and Davis K.L. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am. J. Psychiatry 158 9 (2001) 1441-1448
11. Gibbons R. Mixed effects models for mental health research. Health Serv. Res. Methodol. 1 (2000) 91-129
12. Gurvich T., and Cunningham J.A. Appropriate use of psychotropic drugs in nursing homes. Am. Fam. Phys. 61 5 (2000) 1437-1446
13. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., and Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 8 (2001) 4746-4751
14. Haroutunian V., Davidson M., Kanof P.D., Perl D.P., Powchik P., Losonczy M., McCrystal J., Purohit D.P., Bierer L.M., and Davis K.L. Cortical cholinergic markers in schizophrenia. Schizophr. Res. 12 2 (1994) 137-144
15. Harvey P.D. Cognitive and functional impairments in elderly patients with schizophrenia: a review of the recent literature. Harv. Rev. Psychiatry 9 2 (2001) 59-68
16. Harvey P.D. Cognitive impairment in elderly patients with schizophrenia: age related changes. Int. J. Geriatr. Psychiatry 16 Suppl 1 (2001) S78-S85
17. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 2 (2001) 176-184
18. Harvey P.D., Davidson M., Powchik P., Parrella M., White L., and Mohs R.C. Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr. Res. 7 1 (1992) 85-90
19. Harvey P.D., Parrella M., White L., Mohs R.C., Davidson M., and Davis K.L. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr. Res. 35 1 (1999) 77-84
20. Harvey P.D., Silverman J.M., Mohs R.C., Parrella M., White L., Powchik P., Davidson M., and Davis K.L. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry 45 1 (1999) 32-40
21. Harvey P.D., Bowie C.R., and Friedman J.I. Cognition in schizophrenia. Curr. Psychiatry Rep. 3 5 (2001) 423-428
22. Harvey P.D., Bertisch H., Friedman J.I., Marcus S., Parrella M., White L., and Davis K.L. The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change. Am. J. Geriatr. Psychiatry 11 6 (2003) 610-619
23. Harvey P.D., Napolitano J.A., Mao L., and Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int. J. Geriatr. Psychiatry 18 9 (2003) 820-829
24. Hof P.R., Haroutunian V., Friedrich Jr. V.L., Byne W., Buitron C., Perl D.P., and Davis K.L. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 53 12 (2003) 1075-1085
25. Jann M.W. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 24 12 (2004) 1759-1783
26. Jeste D.V., Barak Y., Madhusoodanan S., Grossman F., and Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 11 6 (2003) 638-647
27. Kay S.R., Opler L.A., and Fiszbein A. Positive and Negative Syndrome Scale User's Manual (2006), Multi-Health Systems Inc., North Tonawanda, New York
28. Keefe R.S., Frescka E., Apter S.H., Davidson M., Macaluso J.M., Hirschowitz J., and Davis K.L. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am. J. Psychiatry 153 6 (1996) 806-811
29. Kennedy J.S., Jeste D., Kaiser C.J., Golshan S., Maguire G.A., Tollefson G., Sanger T., Bymaster F.P., Kinon B.J., Dossenbach M., Gilmore J.A., and Breier A. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int. J. Geriatr. Psychiatry 18 11 (2003) 1013-1020
30. Kincaid M.M., Harvey P.D., Parrella M., White L., Putnam K.M., Powchik P., Davidson M., and Mohs R.C. Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J. Neuropsychiatry Clin. Neurosci. 7 1 (1995) 76-81
31. Kurtz M.M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr. Res. 74 1 (2005) 15-26
32. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
33. Masand P.S., and Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 20 15 (2003) 1099-1100
34. McBride T., Moberg P.J., Arnold S.E., Mozley L.H., Mahr R.N., Gibney M., Kumar A., and Gur R.E. Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophr. Res. 55 32 (2002) 17-27
35. McShane R., Keene J., Gedling K., Fairburn C., Jacoby R., and Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 314 7076 (1997) 266-270
36. Mohs, R.C., 1989. Alzheimer's Disease Assessment Scale-Late Stage Version (ADAS-L) Manual. Unpublished rating manual, Mt Sinai School of Medicine, New York, NY.
37. Nich C., and Carroll K. Now you see it, now you don't: a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial. J. Consult. Clin. Psychol. 65 2 (1997) 252-261
38. Powchik P., Davidson M., Haroutunian V., Gabriel S.M., Purohit D.P., Perl D.P., Harvey P.D., and Davis K.L. Postmortem studies in schizophrenia. Schizophr. Bull. 24 3 (1998) 325-341
39. Purohit D.P., Perl D.P., Haroutunian V., Powchik P., Davidson M., and Davis K.L. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch. Gen. Psychiatry 55 3 (1998) 205-211 (Mar)
40. Rosen W.G., Mohs R.C., and Davis K.D. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 11 (1984) 1356-1364
41. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 14 3 (2006) 191-210
42. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 14 2 (2002) 123-129